June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Effect of ONO-9054 on Aqueous Humor Dynamics in Monkeys
Author Affiliations & Notes
  • Tomohiro Karakawa
    ONO PHARMACEUTICAL CO., LTD, Mishimagun, Japan
  • Shinsaku Yamane
    ONO PHARMACEUTICAL CO., LTD, Mishimagun, Japan
  • Kazufumi Nagai
    ONO PHARMACEUTICAL CO., LTD, Mishimagun, Japan
  • Shintaro Nakao
    ONO PHARMACEUTICAL CO., LTD, Mishimagun, Japan
  • Tsutomu Shiroya
    ONO PHARMACEUTICAL CO., LTD, Mishimagun, Japan
  • Yutaka Shichino
    ONO PHARMACEUTICAL CO., LTD, Mishimagun, Japan
  • Footnotes
    Commercial Relationships Tomohiro Karakawa, ONO PHARMACETICAL CO., LTD (E); Shinsaku Yamane, ONO PHARMACEUTICAL CO., LTD. (E); Kazufumi Nagai, ONO PHARMACEUTICAL CO.,LTD (E); Shintaro Nakao, ONO Pharmaceutical Co.,LTD (E); Tsutomu Shiroya, ONO Pharmaceutical.Co.Ltd. (E); Yutaka Shichino, ONO Pharmaceutical Co Ltd (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 1998. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Tomohiro Karakawa, Shinsaku Yamane, Kazufumi Nagai, Shintaro Nakao, Tsutomu Shiroya, Yutaka Shichino; Effect of ONO-9054 on Aqueous Humor Dynamics in Monkeys. Invest. Ophthalmol. Vis. Sci. 2013;54(15):1998.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: ONO-9054 (Ono Pharmaceuticals, Osaka Japan) is a novel prodrug compound. ONO-9054 is an isopropyl ester derivative of the free acid ONO AG-367 that has been classified as a dual FP/EP3 agonist that may be effective in lowering intraocular pressure in humans. The purpose of this study was to investigate the effect of ONO-9054 on the aqueous humor dynamics in cynomolgus monkeys.

Methods: Aqueous humor flow was measured with a fluorophotometer in monkeys. Ophthalmic vehicle, timolol (5000 μg/mL), latanoprost (50 μg/mL) and ONO-9054 (3 μg/mL) were administered topically into the eye, and aqueous humor flow rate and intraocular pressure (IOP) measurements were conducted. Outflow facility was measured by a two-level, constant-pressure perfusion method in monkeys. Latanoprost (50 μg/mL) and ONO-9054 (3 and 30 μg/mL) were administered to the eye unilaterally, and the contralateral eye was administered ophthalmic vehicle solution. Measurements of outflow facility and IOP were conducted.

Results: Timolol, latanoprost, and ONO-9054 reduced IOP. Timolol decreased the aqueous humor flow (0.93 ± 0.16 μL/min) relative to vehicle (1.88 ± 0.13 μL/min). On the other hand, ONO-9054 at 3 μg/mL (2.06 ± 0.24 μL/min) and latanoprost (2.05 ± 0.08 μL/min) had no effect on aqueous humor flow. When compared with the contralateral vehicle-treated eyes (0.62 ± 0.10 μL/min/mmHg), latanoprost had no effect on the outflow facility (0.62 ± 0.11 μL/min/mmHg). Likewise, ONO-9054 at 3 μg/mL had no effect on the outflow facility (0.56 ± 0.08 μL/min/mmHg). On the other hand, ONO-9054 at 30 μg/mL slightly increased outflow facility (0.87 ± 0.09 μL/min/mmHg) relative to contralateral eyes (0.66 ± 0.08 μL/min/mmHg).

Conclusions: ONO-9054, a dual agonist for prostaglandin FP and EP3 receptors, did not have any effect on aqueous humor flow. The present results suggest that the mechanism of IOP-lowing for ONO-9054 appears to involve an enhancement of uveoscleral outflow, similar to the mechanism reported for pure FP receptor agonists, and an effect on conventional outflow pathways.

Keywords: 427 aqueous • 568 intraocular pressure  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×